Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05262530 · ClinicalTrials.gov registry record · Phase 1
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
A Phase 1 study, sponsored by BioNTech SE.
- Terminated
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT05262530 is a Phase 1 study that was terminated before completion, run by BioNTech SE. The registered enrollment target is 73 participants.
The verdict
NCT05262530, a Phase 1 study, was terminated before completion, sponsored by BioNTech SE.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
This study is an open-label, multicenter, Phase I/IIa, dose escalation, safety, and pharmacokinetics (PK) study of BNT142 followed by expansion cohorts in patients with Claudin 6 (CLDN6)-positive advanced tumors.
Interventions
- BIOLOGICAL BNT142
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2025-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05262530
The ClinicalTrials.gov registry entry for NCT05262530 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BNT142 is the first listed.
NCT05262530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05262530 about?
NCT05262530 is a clinical study titled "Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors". This study is an open-label, multicenter, Phase I/IIa, dose escalation, safety, and pharmacokinetics (PK) study of BNT142 followed by expansion cohorts in patients with Claudin 6 (CLDN6)-positive advanced tumors.
What is the current status of trial NCT05262530?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2022-03-22. Estimated completion is 2025-12-22.
What interventions are being tested in trial NCT05262530?
The interventions under investigation include: BNT142 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05262530?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.